Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mersana Therapeutics Presents Positive Data on Next-Gen Antibody-Drug Conjugate Technology

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Conjugation technology advancements further demonstrate stability, activity and selectivity of Mersana’s ADCs.

Mersana Therapeutics, Inc. announced that new data related to its conjugation technology used to create next-generation ADCs is being presented in a poster session at the 2013 Annual Meeting of the American Association for Cancer Research (AACR). AACR is being held April 6-10, 2013 in Washington, D.C. The preclinical data being presented confirms that Mersana’s technology generates cysteine-conjugated ADCs that are stable, highly active and selective in Her-2 expressing tumor models.

In the poster, Mersana details that its technology, which has previously been applied to create lysine-based ADCs, can also be expanded to create cysteine-based ADCs. The data show that conjugation of Mersana’s Fleximer polymer via cysteines in the antibody hinge region overcomes the destabilization of the antibody which has been reported with conventional, direct drug-cysteine linked ADCs. The stabilization with the Fleximer conjugation approach enhances the advantages of Mersana’s polymer approach to ADCs, which include significantly higher capacity for drug payload, superior payload flexibility and improved physicochemical properties. In this research, the benefits were shown in Her-2 expressing cell lines and preclinical models.

“Mersana has previously demonstrated that our Fleximer-based ADCs that utilize lysine modification are highly efficacious,” said Timothy B. Lowinger, Chief Scientific Officer of Mersana. “These data demonstrate that the scope of our conjugation technology can also be expanded to create novel, highly stable cysteine-based ADCs that are highly active, selective and well-tolerated in preclinical tumor models.”

”Research into how we can expand our technology is part of our commitment to creating truly next-generation ADCs that have the potential to address limitations of other technologies,” said Nicholas Bacopoulos, Ph.D., President and Chief Executive Officer of Mersana. “These types of technological advancements will be utilized as we build our proprietary pipeline of ADC candidates and forge collaborations.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
Exposure To Routine Viruses Makes Mice Better Test Subjects
Study shows that infections make mouse immune system act more like that in humans.
Immune Booster Tested in Advanced Merkel Cell Cancer
The immunotherapy drug produced durable responses in many patients.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!